Current Development Status of Cytokines for Cancer Immunotherapy.

IF 3 3区医学 Q2 PHARMACOLOGY & PHARMACY

Biomolecules & Therapeutics Pub Date : 2024-01-01 DOI:10.4062/biomolther.2023.196

Kyoung Song

{"title":"Current Development Status of Cytokines for Cancer Immunotherapy.","authors":"Kyoung Song","doi":"10.4062/biomolther.2023.196","DOIUrl":null,"url":null,"abstract":"<p><p>Cytokines influence the overall cancer immune cycle by triggering tumor antigen expression, antigen presenting, immune cell priming and activation, effector immune cell recruitment and infiltration to cancer, and cancer killing in the tumor microenvironment (TME). Therefore, cytokines have been considered potential anti-cancer immunotherapy, and cytokine-based anti-cancer therapies continue to be an active area of research and development in the field of cancer immunotherapy, with ongoing clinical trials exploring new strategies to improve efficacy and safety. In this review, we examine past and present clinical developments for major anticancer cytokines, including interleukins (IL-2, IL-15, IL-12, IL-21), interferons, TGF-beta, and GM-CSF. We identify the current status and changes in the technology platform being applied to cytokine-based immune anti-cancer therapeutics. Through this, we discuss the opportunities and challenges of cytokine-based immune anti-cancer treatments in the current immunotherapy market and suggest development directions to enhance the clinical use of cytokines as immuno-anticancer drugs in the future.</p>","PeriodicalId":8949,"journal":{"name":"Biomolecules & Therapeutics","volume":"32 1","pages":"13-24"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10762268/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomolecules & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4062/biomolther.2023.196","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Cytokines influence the overall cancer immune cycle by triggering tumor antigen expression, antigen presenting, immune cell priming and activation, effector immune cell recruitment and infiltration to cancer, and cancer killing in the tumor microenvironment (TME). Therefore, cytokines have been considered potential anti-cancer immunotherapy, and cytokine-based anti-cancer therapies continue to be an active area of research and development in the field of cancer immunotherapy, with ongoing clinical trials exploring new strategies to improve efficacy and safety. In this review, we examine past and present clinical developments for major anticancer cytokines, including interleukins (IL-2, IL-15, IL-12, IL-21), interferons, TGF-beta, and GM-CSF. We identify the current status and changes in the technology platform being applied to cytokine-based immune anti-cancer therapeutics. Through this, we discuss the opportunities and challenges of cytokine-based immune anti-cancer treatments in the current immunotherapy market and suggest development directions to enhance the clinical use of cytokines as immuno-anticancer drugs in the future.

查看原文本刊更多论文

用于癌症免疫疗法的细胞因子的发展现状。

细胞因子通过触发肿瘤抗原表达、抗原呈递、免疫细胞唤醒和活化、效应免疫细胞招募和浸润癌症以及在肿瘤微环境（TME）中杀伤癌症，影响整个癌症免疫周期。因此，细胞因子一直被认为是潜在的抗癌免疫疗法，基于细胞因子的抗癌疗法仍然是癌症免疫疗法领域一个活跃的研发领域，目前正在进行的临床试验正在探索提高疗效和安全性的新策略。在这篇综述中，我们研究了主要抗癌细胞因子过去和现在的临床发展，包括白细胞介素（IL-2、IL-15、IL-12、IL-21）、干扰素、TGF-beta 和 GM-CSF。我们确定了应用于基于细胞因子的免疫抗癌疗法的技术平台的现状和变化。由此，我们探讨了基于细胞因子的免疫抗癌疗法在当前免疫疗法市场中的机遇和挑战，并提出了未来加强细胞因子作为免疫抗癌药物临床应用的发展方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomolecules & Therapeutics 医学-药学

CiteScore

6.60

自引率

8.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomolecules & Therapeutics (Biomolecules & Therapeutics) (Print ISSN 1976-9148, Online ISSN 2005-4483) is an international, peer-reviewed, open access journal that covers pharmacological and toxicological fields related to bioactive molecules and therapeutics. It was launched in 1993 as "The Journal of Applied Pharmacology (ISSN 1225-6110)", and renamed "Biomolecules & Therapeutics" (Biomol Ther: abbreviated form) in 2008 (Volume 16, No. 1). It is published bimonthly in January, March, May, July, September and November. All manuscripts should be creative, informative, and contribute to the development of new drugs. Articles in the following categories are published: review articles and research articles.